- Home
- OPRT vs CLLS Comparison
OPRT vs CLLS Comparison
Compare OPRT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPRT | CLLS |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.5M | 299.0M |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | OPRT | CLLS |
|---|---|---|
| Price | $5.62 | $4.71 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 361.1K | 147.2K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $712,623,000.00 | $82,551,000.00 |
| Revenue This Year | $27.11 | $32.58 |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | $8.44 | ★ N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $3.45 | $1.10 |
| 52 Week High | $9.25 | $5.48 |
Technical Indicators
Market Signals| Indicator | OPRT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 65.04 | 53.17 |
| Support Level | $4.88 | $4.47 |
| Resistance Level | $5.82 | $5.45 |
| Average True Range (ATR) | 0.21 | 0.30 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 83.47 | 20.41 |
Price Performance
Historical ComparisonAbout OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.